Navigation Links
Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
Date:9/30/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 30 /PRNewswire/ -- A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed by the Indian National Consensus group in collaboration with Max Neeman, a leading India-based Contract Research Organization. The goal is to provide simple management to the Type II Diabetes patient dependent on insulin.  The study will bring out a comparison between the routine clinical practice and the therapy decided as per the Insulin guidelines.

This large Phase IV study encompasses the northern, southern, western and eastern parts of India with over 1,200 sites and aims to enroll over 25,000 Type II Diabetics. Max Neeman is responsible for site management of all locations across the country and for achieving the enrollment target. To date, the team has successfully enrolled over 12,000 patients in 2 months time and will achieve the target before the stipulated time.

Max Neeman is experienced in endocrinology/metabolic studies having been awarded numerous diabetic trials to date with 98% patient retention rate and target enrollment met by the deadline.

About Max Neeman International

Max Neeman International is one of the leading CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
2. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
3. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
4. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
5. International Robotic Urology Symposium 2011
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
8. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
9. Webmedx and NLP International Team to Bring Natural Language Processing Software to Medical Transcription
10. MedWOW International Medical Equipment Platform Adds Seller Ministores
11. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
(Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. ... will create 1,400 jobs throughout Western New ... partnership with the SUNY Polytechnic Institute, includes a major ... Building in Buffalo , as well ... manufacturing facility in Dunkirk . The ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... ... , ... In a new paper published in the latest ... J. Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage ... addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers to ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical ... technology, with highly adaptable algorithms, has been updated to help Emergency Department physicians ... symptoms consistent with Zikas and a travel history to affected regions, or potential ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... trainer and author Ray Clarke poses a question as a challenge for his ... his book, "Being in the Being" (published by Partridge Singapore), Clarke explores the ...
Breaking Medicine News(10 mins):